AstraZeneca chalks up dual regulatory wins in cancer and immunology
Drugmaker AstraZeneca Plc chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments in oncology and immunology.
AstraZeneca said Enhertu, developed in conjunction with Daiichi Sankyo, had received US Food and Drug Administration approval in combination with pertuzumab for the first‑line treatment of HER2‑positive metastatic breast cancer - marking the first new therapy in the category in a decade.
The FTSE 100-listed firm said approval was based on the DESTINY‑Breast09 trial, which showed a 44% reduction in the risk of disease progression or death, with median progression‑free survival exceeding three years compared to the standard THP regimen. The decision also triggered a $150m milestone payment from AstraZeneca to Daiichi Sankyo.
Separately, AstraZeneca said its lupus therapy Saphnelo had been cleared in the European Union for subcutaneous self‑administration via a pre‑filled pen, offering patients the same clinical benefits as intravenous infusion with greater convenience.
The approval was supported by positive phase III TULIP‑SC trial data, which demonstrated a significant reduction in disease activity. AZN added that sales of Saphnelo will be subject to a low‑to‑mid‑teens royalty payable to Bristol‑Myers Squibb, depending on geography.
As of 0855 GMT, AstraZeneca shares were up 0.53% at 13,684p.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
